Karen K. Tan
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Karen K. Tan has a total of 38 co-authors. Here are the top co-authors by number of shared publications:
- Jacinda C. Abdul-Mutakabbir
Department of Pharmacy Practice and Sciences, Skaggs School of Pharmacy and Pharmaceutical Sciences, University of California San Diego, La Jolla, USA
10 shared publications Anna Y. Zhou
Department of Pharmacy, Loma Linda University Medical Center, Loma Linda, California
2 shared publications- Anna Y. Zhou
Loma Linda University Health, Loma Linda, CA, USA
2 shared publications - Annie Wong-Beringer
Titus Family Department of Clinical Pharmacy, Alfred E. Mann School of Pharmacy and Pharmaceutical Sciences, University of Southern California, Los Angeles, CA 90033, USA
2 shared publications - Caleb C. McLeod
Department of Pharmacy Practice, Loma Linda University School of Pharmacy, Loma Linda, CA, USA
2 shared publications Hadeel Al-Fayiz
Department of Pharmacy Practice, Loma Linda University School of Pharmacy, Loma Linda, CA, USA
2 shared publications
Latest Publications
- Open Access
- 10 April 2025
- Published by Cambridge University Press (CUP) in Infection Control & Hospital Epidemiology
- Vol. 46 (6) , 654-655
Social vulnerability influences racial and ethnic disparities in Clostridioides difficile infection outcomes
- 10 April 2025
- Published by Cambridge University Press (CUP) in Infection Control & Hospital Epidemiology
- Vol. 46 (6) , 654-655
Open AccessSocial vulnerability influences racial and ethnic disparities in Clostridioides difficile infection outcomes
- Open Access
- 26 June 2024
- Published by Springer Nature in Infectious Diseases and Therapy
- Vol. 13 (8) , 1807-1819
Characterizing Day 1 Area Under the Curve Following Vancomycin Loading Dose Administration in Adult Hospitalized Patients Using Non-Trapezoidal Linear Pharmacokinetic Equations: A Retrospective Observational Study
Introduction Methicillin-resistant Staphylococcus aureus (MRSA) infections are a serious threat to public health. Vancomycin (VAN) remains the primary treatment for these infections, and achieving the recommended area under the curve (AUC) target has been linked to improved clinical outcomes. The current VAN therapeutic monitoring guidelines recommend a loading dose (LD) of 20–35 mg/kg to rapidly attain targeted VAN exposures within 24 h of therapy. However, there is a paucity of data describing the impact of VAN LD on day 1 area under the curve (AUC0–24). This study aims to employ pharmacokinetic (PK) equations to calculate and describe the AUC0–24 following a VAN LD of 20 mg/kg. Methods This was a retrospective study of adult patients who were loaded with VAN 20 mg/kg, received ≥ 48 h of treatment, and had two consecutive serum VAN levels collected within 24 h. Linear, non-trapezoidal PK equations and two post-infusion VAN levels were used to calculate AUC0–24. Therapeutic AUC0–24 was defined as 400–600 mg/l*h. Results Among 123 included patients, the median age was 46 years (IQR 36, 62), 54% (67/123) of the patients had a body mass index (BMI) ≥ 30 kg/m2 and 27% (33/123) were admitted to the intensive care unit (ICU). Following a LD of 20 mg/kg, 50% (61/123) of the patients met the therapeutic AUC0–24, while 22% (27/123) of the patients were subtherapeutic, and 28% (35/123) were supratherapeutic. Compared with patients who achieved therapeutic AUC0–24, patients with subtherapeutic AUC0–24 were more likely to be younger (44 vs. 37 years old) and have a BMI ≥ 30 kg/m2 (67 vs. 52%). In contrast, patients with supratherapeutic AUC0–24 were more likely to be older (64 vs. 44 years old) and to have chronic kidney disease diagnosis (23 vs. 7%) when compared to patients who achieved a therapeutic AUC0–24. Conclusions Only 50% of patients achieve the target AUC0-24 following a VAN 20 mg/kg LD, with younger, heavier patients underexposed and older patients with renal impairment overexposed, suggesting that different dosing strategies are needed for these populations.
- 26 June 2024
- Published by Springer Nature in Infectious Diseases and Therapy
- Vol. 13 (8) , 1807-1819
Open AccessCharacterizing Day 1 Area Under the Curve Following Vancomycin Loading Dose Administration in Adult Hospitalized Patients Using Non-Trapezoidal Linear Pharmacokinetic Equations: A Retrospective Observational Study
Introduction Methicillin-resistant Staphylococcus aureus (MRSA) infections are a serious threat to public health. Vancomycin (VAN) remains the primary treatment for these infections, and achieving the recommended area under the curve (AUC) target has been linked to improved clinical outcomes. The current VAN therapeutic monitoring guidelines recommend a loading dose (LD) of 20–35 mg/kg to rapidly attain targeted VAN exposures within 24 h of therapy. However, there is a paucity of data describing the impact of VAN LD on day 1 area under the curve (AUC0–24). This study aims to employ pharmacokinetic (PK) equations to calculate and describe the AUC0–24 following a VAN LD of 20 mg/kg. Methods This was a retrospective study of adult patients who were loaded with VAN 20 mg/kg, received ≥ 48 h of treatment, and had two consecutive serum VAN levels collected within 24 h. Linear, non-trapezoidal PK equations and two post-infusion VAN levels were used to calculate AUC0–24. Therapeutic AUC0–24 was defined as 400–600 mg/l*h. Results Among 123 included patients, the median age was 46 years (IQR 36, 62), 54% (67/123) of the patients had a body mass index (BMI) ≥ 30 kg/m2 and 27% (33/123) were admitted to the intensive care unit (ICU). Following a LD of 20 mg/kg, 50% (61/123) of the patients met the therapeutic AUC0–24, while 22% (27/123) of the patients were subtherapeutic, and 28% (35/123) were supratherapeutic. Compared with patients who achieved therapeutic AUC0–24, patients with subtherapeutic AUC0–24 were more likely to be younger (44 vs. 37 years old) and have a BMI ≥ 30 kg/m2 (67 vs. 52%). In contrast, patients with supratherapeutic AUC0–24 were more likely to be older (64 vs. 44 years old) and to have chronic kidney disease diagnosis (23 vs. 7%) when compared to patients who achieved a therapeutic AUC0–24. Conclusions Only 50% of patients achieve the target AUC0-24 following a VAN 20 mg/kg LD, with younger, heavier patients underexposed and older patients with renal impairment overexposed, suggesting that different dosing strategies are needed for these populations.
- Open Access
- 3 May 2024
- Published by Cambridge University Press (CUP) in Antimicrobial Stewardship & Healthcare Epidemiology
- Vol. 4 (1) , e74
Prioritizing Equity in Antimicrobial Stewardship Efforts (EASE): a framework for infectious diseases clinicians
Health equity gaps persist across minoritized groups due to systems of oppression affecting health-related social needs such as access to transportation, education and literacy, or food and housing security. Consequently, disparities in the prevalence of multidrug-resistant infections, infectious disease outcomes, and inappropriate antimicrobial use have been reported across minoritized populations. The Joint Commission and Centers for Medicare and Medicaid Services (CMS) have formally acknowledged the importance of integrating health equity-focused initiatives into existing hospital quality improvement (QI) programs. Here, we review documented disparities in antimicrobial stewardship and offer a framework, derived from components of existing health equity and QI tools, to guide clinicians in prioritizing equity in antimicrobial stewardship efforts (EASE).
- 3 May 2024
- Published by Cambridge University Press (CUP) in Antimicrobial Stewardship & Healthcare Epidemiology
- Vol. 4 (1) , e74
Open AccessPrioritizing Equity in Antimicrobial Stewardship Efforts (EASE): a framework for infectious diseases clinicians
Health equity gaps persist across minoritized groups due to systems of oppression affecting health-related social needs such as access to transportation, education and literacy, or food and housing security. Consequently, disparities in the prevalence of multidrug-resistant infections, infectious disease outcomes, and inappropriate antimicrobial use have been reported across minoritized populations. The Joint Commission and Centers for Medicare and Medicaid Services (CMS) have formally acknowledged the importance of integrating health equity-focused initiatives into existing hospital quality improvement (QI) programs. Here, we review documented disparities in antimicrobial stewardship and offer a framework, derived from components of existing health equity and QI tools, to guide clinicians in prioritizing equity in antimicrobial stewardship efforts (EASE).
- Open Access
- 4 January 2024
- Published by MDPI AG in Antibiotics
- Vol. 13 (1) , 47
Determining Susceptibility and Potential Mediators of Resistance for the Novel Polymyxin Derivative, SPR206, in Acinetobacter baumannii
With the increase in carbapenem-resistant A. baumannii (CRAB) infections, there has been a resurgence in the use of polymyxins, specifically colistin (COL). Since the reintroduction of COL-based regimens in treating CRAB infections, several COL-resistant A. baumannii isolates have been identified, with the mechanism of resistance heavily linked with the loss of the lipopolysaccharide (LPS) layer of the bacterial outer membrane through mutations in lpxACD genes or the pmrCAB operon. SPR206, a novel polymyxin derivative, has exhibited robust activity against multidrug-resistant (MDR) A. baumannii. However, there is a dearth of knowledge regarding its efficacy in comparison with other A. baumannii-active therapeutics and whether traditional polymyxin (COL) mediators of A. baumannii resistance also translate to reduced SPR206 activity. Here, we conducted susceptibility testing using broth microdilution on 30 A. baumannii isolates (17 COL-resistant and 27 CRAB), selected 14 COL-resistant isolates for genomic sequencing analysis, and performed time-kill analyses on four COL-resistant isolates. In susceptibility testing, SPR206 demonstrated a lower range of minimum inhibitory concentrations (MICs) compared with COL, with a four-fold difference observed in MIC50 values. Mutations in lpxACD and/or pmrA and pmrB genes were detected in each of the 14 COL-resistant isolates; however, SPR206 maintained MICs ≤ 2 mg/L for 9/14 (64%) of the isolates. Finally, SPR206-based combination regimens exhibited increased synergistic and bactericidal activity compared with COL-based combination regimens irrespective of the multiple resistance genes detected. The results of this study highlight the potential utility of SPR206 in the treatment of COL-resistant A. baumannii infections.
- 4 January 2024
- Published by MDPI AG in Antibiotics
- Vol. 13 (1) , 47
Open AccessDetermining Susceptibility and Potential Mediators of Resistance for the Novel Polymyxin Derivative, SPR206, in Acinetobacter baumannii
With the increase in carbapenem-resistant A. baumannii (CRAB) infections, there has been a resurgence in the use of polymyxins, specifically colistin (COL). Since the reintroduction of COL-based regimens in treating CRAB infections, several COL-resistant A. baumannii isolates have been identified, with the mechanism of resistance heavily linked with the loss of the lipopolysaccharide (LPS) layer of the bacterial outer membrane through mutations in lpxACD genes or the pmrCAB operon. SPR206, a novel polymyxin derivative, has exhibited robust activity against multidrug-resistant (MDR) A. baumannii. However, there is a dearth of knowledge regarding its efficacy in comparison with other A. baumannii-active therapeutics and whether traditional polymyxin (COL) mediators of A. baumannii resistance also translate to reduced SPR206 activity. Here, we conducted susceptibility testing using broth microdilution on 30 A. baumannii isolates (17 COL-resistant and 27 CRAB), selected 14 COL-resistant isolates for genomic sequencing analysis, and performed time-kill analyses on four COL-resistant isolates. In susceptibility testing, SPR206 demonstrated a lower range of minimum inhibitory concentrations (MICs) compared with COL, with a four-fold difference observed in MIC50 values. Mutations in lpxACD and/or pmrA and pmrB genes were detected in each of the 14 COL-resistant isolates; however, SPR206 maintained MICs ≤ 2 mg/L for 9/14 (64%) of the isolates. Finally, SPR206-based combination regimens exhibited increased synergistic and bactericidal activity compared with COL-based combination regimens irrespective of the multiple resistance genes detected. The results of this study highlight the potential utility of SPR206 in the treatment of COL-resistant A. baumannii infections.
- Open Access
- 29 November 2023
- Published by Cambridge University Press (CUP) in Antimicrobial Stewardship & Healthcare Epidemiology
- Vol. 3 (1) , e214
Examining racial and social vulnerability disparities in the outpatient treatment of uncomplicated cystitis at a Southern California Academic Hospital
Racially and ethnically minoritized (REM) patients are disproportionately impacted by infectious diseases. In our study, REM patients were more likely to receive care for urinary tract infections in the emergency department or urgent care, were younger, and were more likely to have higher social vulnerability.
- 29 November 2023
- Published by Cambridge University Press (CUP) in Antimicrobial Stewardship & Healthcare Epidemiology
- Vol. 3 (1) , e214
Open AccessExamining racial and social vulnerability disparities in the outpatient treatment of uncomplicated cystitis at a Southern California Academic Hospital
Racially and ethnically minoritized (REM) patients are disproportionately impacted by infectious diseases. In our study, REM patients were more likely to receive care for urinary tract infections in the emergency department or urgent care, were younger, and were more likely to have higher social vulnerability.
- Open Access
- 27 November 2023
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 10 (Supplement)
586. Characterizing the Clinical Outcomes of Patients with Positive Blood Cultures Not Identified by Rapid Diagnostics
Rapid diagnostics tools (RDTs) have improved clinical outcomes by prompt identification of pathogens in blood cultures, leading to the initiation of directed empiric antibiotic therapy. However, several organisms are unidentified by RDTs, which may delay appropriate antimicrobial therapy and increase mortality risks. Studies characterizing these off-panel organisms are limited, and guidance for antimicrobial therapy is unavailable. We sought to characterize the off-panel organisms encountered in blood cultures and provide important insights into the pathogens that may be missed by RDTs to improve the clinical management of bacteremia. This was a retrospective study conducted from 8/2018 to 5/2021 at an academic medical center in Loma Linda, California. All adult patients with blood cultures processed on the Verigene (RDT) platform were screened for inclusion. Patients were included if Verigene was unable to detect a target organism. Species identification and antimicrobial susceptibility were performed with MicroScan WalkAway or sent to a reference laboratory if unidentifiable by MicroScan. Patient demographics, comorbidities, suspected source of infection, discharge disposition, and readmissions were determined by chart review. Out of 1,071 blood cultures screened, 80 (47 Gram-positive [GP] and 33 Gram-negative [GN] isolates were not identified by Verigene. While not significant, patients with off-panel GN bacteremia were older (65.5 vs 58 years, p=0.074) and had longer durations of stay (11 vs 9 days, p=0.149) than patients with unidentified GP isolates. Patients with off-panel GN isolates were also more likely to have a comorbid malignancy than those with off-panel GP isolates (42% vs 26%, p=0.112) and more likely to present with severe sepsis (89% vs 79%, p =0.376), though these differences were not significant. Cefepime and piperacillin/tazobactam were reliable agents for GN isolates (11/13, 18/21), and vancomycin retained activity against unidentified GP isolates. Patients with GN organisms not identified by RDTs are more likely to present with severe sepsis and less likely to survive hospital discharge than those with unidentified GP organisms. Further research is needed to guide antimicrobial therapy for off-panel results. Jacinda Abdul-Mutkabbir, PharmD,MPH, Entasis Therapeutics: Advisor/Consultant|Entasis Therapeutics: Honoraria|shionogi: Advisor/Consultant|shionogi: Honoraria
- 27 November 2023
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 10 (Supplement)
Open Access586. Characterizing the Clinical Outcomes of Patients with Positive Blood Cultures Not Identified by Rapid Diagnostics
Rapid diagnostics tools (RDTs) have improved clinical outcomes by prompt identification of pathogens in blood cultures, leading to the initiation of directed empiric antibiotic therapy. However, several organisms are unidentified by RDTs, which may delay appropriate antimicrobial therapy and increase mortality risks. Studies characterizing these off-panel organisms are limited, and guidance for antimicrobial therapy is unavailable. We sought to characterize the off-panel organisms encountered in blood cultures and provide important insights into the pathogens that may be missed by RDTs to improve the clinical management of bacteremia. This was a retrospective study conducted from 8/2018 to 5/2021 at an academic medical center in Loma Linda, California. All adult patients with blood cultures processed on the Verigene (RDT) platform were screened for inclusion. Patients were included if Verigene was unable to detect a target organism. Species identification and antimicrobial susceptibility were performed with MicroScan WalkAway or sent to a reference laboratory if unidentifiable by MicroScan. Patient demographics, comorbidities, suspected source of infection, discharge disposition, and readmissions were determined by chart review. Out of 1,071 blood cultures screened, 80 (47 Gram-positive [GP] and 33 Gram-negative [GN] isolates were not identified by Verigene. While not significant, patients with off-panel GN bacteremia were older (65.5 vs 58 years, p=0.074) and had longer durations of stay (11 vs 9 days, p=0.149) than patients with unidentified GP isolates. Patients with off-panel GN isolates were also more likely to have a comorbid malignancy than those with off-panel GP isolates (42% vs 26%, p=0.112) and more likely to present with severe sepsis (89% vs 79%, p =0.376), though these differences were not significant. Cefepime and piperacillin/tazobactam were reliable agents for GN isolates (11/13, 18/21), and vancomycin retained activity against unidentified GP isolates. Patients with GN organisms not identified by RDTs are more likely to present with severe sepsis and less likely to survive hospital discharge than those with unidentified GP organisms. Further research is needed to guide antimicrobial therapy for off-panel results. Jacinda Abdul-Mutkabbir, PharmD,MPH, Entasis Therapeutics: Advisor/Consultant|Entasis Therapeutics: Honoraria|shionogi: Advisor/Consultant|shionogi: Honoraria
- Open Access
- 27 November 2023
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 10 (Supplement)
1858. Examining the Racial Differences in Polymicrobial Bacteremia Infections in an Area of Varying Social Vulnerability
Polymicrobial bacteremia (PMB) is associated with heightened disease severity and an increased burden of comorbidities has been identified as a key risk factor. Of interest, racially and ethnically minoritized (REM) individuals that reside in areas of high vulnerability have been shown to be more likely than their non-racially and ethnically minoritized (n-REM) counterparts to be diagnosed with chronic comorbidities. Nonetheless, there is a cessation of data that examines the confluence of these factors on PMB infection outcomes. This study aims to describe the racial differences in the outcomes of patients diagnosed with PMB in an area of varying social vulnerability. This is an IRB-approved, retrospective cohort study of adult patients hospitalized at Loma Linda University Medical Center between January 2018 and April 2021. Positive polymicrobial blood culture samples were identified with the use of Microscan Bacterial Identification Panel. Demographics (including race/ethnicity), comorbid conditions, sepsis incidence, and infection source were collected through chart review. The Centers for Disease Control and Prevention (CDC) SVI scoring tool was used to determine the social vulnerability index (SVI). A P value of ≤ 0.05 was defined as statistically significant. A total of 70 patients REM (60%, 42/70) and non-REM (40%, 28/70) among PMB gram-negative (GN) and gram-positive (GP) cultures collected from hospitalized adult patients were included. Hispanic/Latino was the most prominent REM group (59.5%) and overall, REM patients were more likely to be classified as “highly vulnerable” when compared to non-REM patients (47.6% vs 42.9%). Also, REM patients were younger (61.5 years vs. 65.1 years) and were more likely to have underlying comorbidities (diabetes mellitus (47.6% vs 21.4%; p=0.026 and moderate to severe chronic kidney disease (28.8% vs 14.3%; p= 0.329). Additionally, REM patients were more likely to develop sepsis and severe sepsis (45.2% vs. 25.0%; p= 0.13 and 40.6% vs 35.7%, p=0.804), respectively, though there was no difference in mortality. Ultimately, further research is needed to understand the confluence of race/ethnicity and social vulnerability factors on PMB clinical outcomes. Jacinda C. Abdul-Mutakabbir, PharmD, MPH, Entasis: Advisor/Consultant|Entasis: Honoraria|Shionogi: Advisor/Consultant|Shionogi: Honoraria
- 27 November 2023
- Published by Oxford University Press (OUP) in Open Forum Infectious Diseases
- Vol. 10 (Supplement)
Open Access1858. Examining the Racial Differences in Polymicrobial Bacteremia Infections in an Area of Varying Social Vulnerability
Polymicrobial bacteremia (PMB) is associated with heightened disease severity and an increased burden of comorbidities has been identified as a key risk factor. Of interest, racially and ethnically minoritized (REM) individuals that reside in areas of high vulnerability have been shown to be more likely than their non-racially and ethnically minoritized (n-REM) counterparts to be diagnosed with chronic comorbidities. Nonetheless, there is a cessation of data that examines the confluence of these factors on PMB infection outcomes. This study aims to describe the racial differences in the outcomes of patients diagnosed with PMB in an area of varying social vulnerability. This is an IRB-approved, retrospective cohort study of adult patients hospitalized at Loma Linda University Medical Center between January 2018 and April 2021. Positive polymicrobial blood culture samples were identified with the use of Microscan Bacterial Identification Panel. Demographics (including race/ethnicity), comorbid conditions, sepsis incidence, and infection source were collected through chart review. The Centers for Disease Control and Prevention (CDC) SVI scoring tool was used to determine the social vulnerability index (SVI). A P value of ≤ 0.05 was defined as statistically significant. A total of 70 patients REM (60%, 42/70) and non-REM (40%, 28/70) among PMB gram-negative (GN) and gram-positive (GP) cultures collected from hospitalized adult patients were included. Hispanic/Latino was the most prominent REM group (59.5%) and overall, REM patients were more likely to be classified as “highly vulnerable” when compared to non-REM patients (47.6% vs 42.9%). Also, REM patients were younger (61.5 years vs. 65.1 years) and were more likely to have underlying comorbidities (diabetes mellitus (47.6% vs 21.4%; p=0.026 and moderate to severe chronic kidney disease (28.8% vs 14.3%; p= 0.329). Additionally, REM patients were more likely to develop sepsis and severe sepsis (45.2% vs. 25.0%; p= 0.13 and 40.6% vs 35.7%, p=0.804), respectively, though there was no difference in mortality. Ultimately, further research is needed to understand the confluence of race/ethnicity and social vulnerability factors on PMB clinical outcomes. Jacinda C. Abdul-Mutakabbir, PharmD, MPH, Entasis: Advisor/Consultant|Entasis: Honoraria|Shionogi: Advisor/Consultant|Shionogi: Honoraria
- Open Access
- 4 May 2023
- Published by Cambridge University Press (CUP) in Infection Control & Hospital Epidemiology
- Vol. 44 (11) , 1861-1865
Examining the impact of racial disparities on Clostridioides difficile infection outcomes at a Southern California academic teaching hospital
Racial differences in Clostridioides difficile infection (CDI) outcomes have been reported. In this study, minoritized patients with CDIs had prolonged hospitalizations and increased intensive care unit admissions. Chronic kidney disease was shown to partially mediate the relationship between race or ethnicity and severe CDI. Our findings suggest potential areas for equitable interventions.
- 4 May 2023
- Published by Cambridge University Press (CUP) in Infection Control & Hospital Epidemiology
- Vol. 44 (11) , 1861-1865
Open AccessExamining the impact of racial disparities on Clostridioides difficile infection outcomes at a Southern California academic teaching hospital
Racial differences in Clostridioides difficile infection (CDI) outcomes have been reported. In this study, minoritized patients with CDIs had prolonged hospitalizations and increased intensive care unit admissions. Chronic kidney disease was shown to partially mediate the relationship between race or ethnicity and severe CDI. Our findings suggest potential areas for equitable interventions.
- Open Access
- 24 April 2023
- Published by Cambridge University Press (CUP) in Infection Control & Hospital Epidemiology
- Vol. 44 (11) , 1866-1869
Racial disparities among candidemic patients at a Southern California teaching hospital
Racially and ethnically minoritized (REM) patients are disproportionately affected by infectious diseases, including candidemia. REM patients with candidemia were significantly younger, with trends toward more risk factors for candidemia and longer lengths of stay. Although Candida parapsilosis was more common in REM patients, there were no differences in mortality rates.
- 24 April 2023
- Published by Cambridge University Press (CUP) in Infection Control & Hospital Epidemiology
- Vol. 44 (11) , 1866-1869
Open AccessRacial disparities among candidemic patients at a Southern California teaching hospital
Racially and ethnically minoritized (REM) patients are disproportionately affected by infectious diseases, including candidemia. REM patients with candidemia were significantly younger, with trends toward more risk factors for candidemia and longer lengths of stay. Although Candida parapsilosis was more common in REM patients, there were no differences in mortality rates.
- Open Access
- 1 January 2023
- Published by SAGE Publications in Therapeutic Advances in Infectious Disease
- Vol. 10
Identifying the potential impact of a multidisciplinary outpatient antimicrobial therapy program in an area of high social vulnerability
Background: Outpatient parenteral antimicrobial therapy (OPAT) and complex outpatient antimicrobial therapy (COpAT) are common practice in the management of infectious diseases (IDs). However, providing OPAT/COpAT can pose significant challenges pre- and post-discharge, particularly in vulnerable patient populations. Objectives: The objective of this study is to assess outpatient complications related to OPAT/COpAT in patients discharged with a home health services referral and to identify pre- and post-discharge intervention opportunities and the associated cost-savings that could be achieved with a multidisciplinary ID team-run OPAT/COpAT program. Design/methods: This is a retrospective cohort study of patients who were discharged with OPAT/COpAT through home health services over a 3-month study period. Data on potential pre-discharge interventions and post-discharge complications were recorded. Results: Medication-related issues were the most common pre-discharge complications, accounting for more than 50% of identified intervention opportunities. More than half of the included patients experienced at least one documented outpatient complication post-discharge with peripherally inserted central catheter-line-related complication (20.7%) being the most common issue. Using previously published cost-estimates, the implementation of a designated pre- and post-discharge OPAT/COpAT program could have saved over $100,000 over the 3-month study period. Conclusion: A multidisciplinary OPAT/COpAT program located in a high social vulnerable area can help reduce complications related to a patient’s antimicrobial therapy. Medication-related issues represent a major area for potential intervention. Our findings suggest that a multidisciplinary ID team will have ample opportunities to improve the transition of care, at both pre- and post-discharge, for patients requiring antimicrobial therapy.
- 1 January 2023
- Published by SAGE Publications in Therapeutic Advances in Infectious Disease
- Vol. 10
Open AccessIdentifying the potential impact of a multidisciplinary outpatient antimicrobial therapy program in an area of high social vulnerability
Background: Outpatient parenteral antimicrobial therapy (OPAT) and complex outpatient antimicrobial therapy (COpAT) are common practice in the management of infectious diseases (IDs). However, providing OPAT/COpAT can pose significant challenges pre- and post-discharge, particularly in vulnerable patient populations. Objectives: The objective of this study is to assess outpatient complications related to OPAT/COpAT in patients discharged with a home health services referral and to identify pre- and post-discharge intervention opportunities and the associated cost-savings that could be achieved with a multidisciplinary ID team-run OPAT/COpAT program. Design/methods: This is a retrospective cohort study of patients who were discharged with OPAT/COpAT through home health services over a 3-month study period. Data on potential pre-discharge interventions and post-discharge complications were recorded. Results: Medication-related issues were the most common pre-discharge complications, accounting for more than 50% of identified intervention opportunities. More than half of the included patients experienced at least one documented outpatient complication post-discharge with peripherally inserted central catheter-line-related complication (20.7%) being the most common issue. Using previously published cost-estimates, the implementation of a designated pre- and post-discharge OPAT/COpAT program could have saved over $100,000 over the 3-month study period. Conclusion: A multidisciplinary OPAT/COpAT program located in a high social vulnerable area can help reduce complications related to a patient’s antimicrobial therapy. Medication-related issues represent a major area for potential intervention. Our findings suggest that a multidisciplinary ID team will have ample opportunities to improve the transition of care, at both pre- and post-discharge, for patients requiring antimicrobial therapy.